Clotting times of patient plasmas (patients 1-11) measured by a partial thromboplastin time assay. (A) Severe hemophilia B; (B) mild hemophilia B; (C) moderate hemophilia B. Different concentrations of FIXa were added to patient plasmas (1-11), and the clotting times were measured in the absence (red bar) and presence (green bar) of PS antibody. Different panels were created based on the severity of FIX deficiency. Patient samples 1, 2, 8, 9, and 10 are from patients with severe HB who were administered EHL. Patient 6 had severe HB and was treated with SHL. Patient samples 3, 4, 5, and 7 were from patients with mild HB treated with SHL, and patient 11 had moderate hemophilia, treated with an EHL product.

Clotting times of patient plasmas (patients 1-11) measured by a partial thromboplastin time assay. (A) Severe hemophilia B; (B) mild hemophilia B; (C) moderate hemophilia B. Different concentrations of FIXa were added to patient plasmas (1-11), and the clotting times were measured in the absence (red bar) and presence (green bar) of PS antibody. Different panels were created based on the severity of FIX deficiency. Patient samples 1, 2, 8, 9, and 10 are from patients with severe HB who were administered EHL. Patient 6 had severe HB and was treated with SHL. Patient samples 3, 4, 5, and 7 were from patients with mild HB treated with SHL, and patient 11 had moderate hemophilia, treated with an EHL product.

Close Modal

or Create an Account

Close Modal
Close Modal